Gain of chromosome 17q material is the most frequent genetic abnormality in neuroblastomas. The common region of gain is at least 375 cR large, which has precluded the identi®cation of genes with a role in neuroblastoma pathogenesis. Neuroblastoma also frequently show ampli®cation of the N-myc oncogene, which correlates closely with 17q gain. Both events are strong predictors of unfavorable prognosis. To identify genes that are part of the N-myc downstream pathway, we constructed SAGE libraries of an N-myc transfected and a control cell line. This identi®ed the chromosome 17q genes nm23-H1 and nm23-H2 as being 6 ± 10 times induced in the N-myc expressing cells. Northern and Western blot analysis con®rmed this up-regulation. Time-course experiment shows that both genes are induced within 4 h after N-myc is switched on. Furthermore, we demonstrate also that c-myc can upregulate nm23-H1 and nm23-H2 expression. Neuroblastoma tumor and cell line panels reveal a striking correlation between N-myc ampli®cation and mRNA and protein expression of both nm23 genes. We show that the nm23 genes are located at the edge of the common region of chromosome 17q gain previously described in neuroblastoma cell lines. Our ®ndings suggest that nm23-H1 and nm23-H2 expression is increased by 17q gain in neuroblastoma and can be further up-regulated by myc overexpression. These observations suggest a major role for nm23-H1 and nm23-H2 in tumorigenesis of unfavorable neuroblastomas.
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Keywords: nm23-H1; nm23-H2; N-myc;, c-myc; chromosome 17; neuroblastoma Neuroblastoma is a solid tumor of early childhood and originates from neural crest derived cells. The N-myc oncogene is ampli®ed in a subgroup of the tumors and correlates with an unfavorable outcome (Brodeur et al., 1984) . In addition, gain of chromosome 17q is the most frequent genetic abnormality with an incidence varying from 40 to 80% (Caron et al., 1995) . Previous reports have shown that 17q gain is an important prognostic factor, independent of chromosome 1p loss and N-myc ampli®cation (Bown et al., 1999) . Gain of 17q is correlated with N-myc ampli®cation, as almost all Nmyc ampli®ed neuroblastomas have 17q gain (Bown et al., 1999) . Several studies on neuroblastoma tissue have identi®ed a common ampli®ed region from 17q21.3 ± 17qter, corresponding to a distance of approximately 60 cM or 375 cR (Lastowska et al., 1998; Meddeb et al., 1996) .
The nm23-H1 and nm23-H2 genes map within 4 kb of each other to chromosome 17q21.3. They are members of a highly conserved family of eight nucleoside diphosphate kinases (NDPK) (Backer et al., 1993) . Nm23-H1 and H2 encode for the polypeptide subunits NDPK-A and NDPK-B respectively, which assemble to heterohexameric enzymes. They are required for the synthesis of nucleoside triphosphates (NTP) other than ATP. However, it is presumed that this gene family exerts other functions as well. A mutation in the Drosophila homologue of nm23, in combination with a defect in the prune gene, severely aects the development of the¯y without aecting the NDP kinase activity (Lombardi et al., 2000) .
High expression of human nm23-H1 is associated with a decreased metastatic potential in dierent cancers, e.g. breast cancer and melanomas (Florenes et al., 1992) . In contrast, in other cancers like prostate cancer, non-Hodgkin lymphomas and neuroblastoma, a high nm23-H1 expression is associated with an adverse outcome (Niitsu et al., 2001) .
As N-myc ampli®cation and 17q gain are closely correlated in neuroblastoma, we searched for N-myc regulated genes located on chromosome 17q. To identify genes that are part of the N-myc downstream pathway, we have applied the SAGE technology. SAGE can generate expression pro®les of all mRNA's expressed in a tissue or cell line. It is based on the extraction of a 10 bp tag from a ®xed position in each mRNA. We compared SAGE libraries of the N-myc transfected neuroblastoma cell line SHEP-21N and the mock transfected control cell line SHEP-2 (Boon et al., 2001) . We sequenced 44.301 mRNA tags of SHEP-2 and 34 462 mRNA tags of the SHEP-21N library. We found the SAGE tags of the two 17q genes nm23-H1 and H2 to be signi®cantly higher in the N-myc transfected cell line. The nm23-H1 expression level increases from 2.0 per 30 000 tags in SHEP-2 to 20.6 per 30 000 tags in SHEP-21N (10.3-fold). Nm23-H2 is up-regulated from 4.7 per 30 000 tags in SHEP-2 to 31.4 per 30 000 tags in SHEP-21N (6.7-fold). The upregulation of nm23-H1 and nm23-H2 in SHEP-21N was con®rmed by Northern and also Western blot analysis ( Figure 1a) .
N-myc expression in the SHEP-21N cell line can be switched o by tetracycline (Lutz et al., 1996) . In a time-course experiment we show that N-myc is switched o within 8 h after adding tetracycline ( Figure  1b) . Within 24 h after adding tetracycline, the mRNA levels of both nm23-H1 and nm23-H2 are reduced to a level comparable to that of the mock transfected SHEP-2 cell line. Removing tetracycline from the culture medium restored N-myc expression within 4 h. Nm23-H1 and nm23-H2 are re-induced within 4 h after N-myc was re-expressed. This indicates that both genes are induced early in the N-myc downstream cascade, although they are not necessarily a direct target of N-myc.
We studied the expression of nm23-H1 and H2 in a neuroblastoma panel consisting of 21 tumors and 22 cell lines. A striking correlation of N-myc and nm23 mRNA expression was found among the cell lines (Figure 2 ). In 13 out of 14 N-myc ampli®ed neurobastoma cell lines both nm23-H1 and H2 are highly expressed. The N-myc single copy cell lines generally have a weak expression of both genes. SK-N-AS, SJNB-12 and GI-MEN cell lines have a rather high nm23-H1 and H2 expression. These N-myc single copy cell lines have high c-myc expression (Cheng et al., 1996) . Also the tumor panel showed a clear correlation between N-myc expression and nm23-H1 and H2 expression ( Figure 3 ). The majority of the N-myc ampli®ed tumors have a high nm23-H1 and H2 expression. Four of the 11 N-myc single copy tumors (N68, N98, N99, N160) show a relatively high expression of nm23-H1 and H2. This indicates that also other mechanism of nm23 up-regulation exist in neuroblastoma. Together with the cell line results these 21N , and the melanoma cell lines MD3A and E10. Northern blot analysis was performed according to standard procedure. Brie¯y, 15 mg of total mRNA was separated on a denaturing gel, blotted to Hybond nylon membrane and hybridized. SHEP-21N has ectopic N-myc expression (Lutz et al., 1996) and E10 has ectopic c-myc expression (Versteeg et al., 1988) , SHEP-2 and MD3A are mock transfected controls. Up-regulation of nm23-H1 and nm23-H2 is shown in SHEP-21N and E10. The co®lin gene and a probe for the 28S ribosomal RNA subunit were used for loading controls. Right: Western blot analysis of N-MYC, NM23-H1 and H2. Aliquots of 2mg total protein lysates of SHEP-2 and SHEP-21N were run on 15% polyacrylamide SDS gel and transferred to a PVDF membrane. Up-regulated NM23-H1 and H2 protein expression was detected in SHEP-21N after hybridization with NM23-H1 and H2 polyclonal anti-bodies (Pinon et al., 1999) . Subsequently, the ®lter was stripped and re-hybridized with monoclonal N-MYC antibodies (Pharmingen). For equal loading Coomassie stained gel are shown. (b) Northern blot analysis of a time-course experiment showing induction of nm23-H1 and nm23-H2 within 4 h after upregulation of N-myc. In the SHEP-21N cell line the expression of the N-myc construct can be down-regulated by adding tetracycline to the medium. Tetracycline (Sigma) was used at a concentration of 10 ng/ml medium to inhibit N-myc expression. The ®rst three lanes contain total RNA from SHEP-21N isolated at 0, 8 and 24 h after addition of tetracycline. The following eight lanes are total RNA isolates of SHEP-21N at 1, 2, 4, 6, 10, 12 and 24 h after removing tetracycline. The Northern blot was hybridized as in a. Nmyc is switched o within 8 h after the start of tetracycline treatment and re-expressed within 4 h after removal of tetracycline. Nm23-H1 and H2 are down-regulated after switching o N-myc. Within 4 h after N-myc re-expression the activity of both genes are restored These ®ndings raise the hypothesis that nm23-H1 and H2 expression is up-regulated by an increase in gene copy number, which is further boosted by N-myc over-expression. To further study this possible mechanism, we analysed the relation between nm23 copy number and expression level. The cell line panel could not be used for this purpose, as both N-myc ampli®ed and single copy cell lines have extra copies of chromosome 17q including the two nm23 genes (Lastowska et al., 1998; Van Roy et al., 1995) . We therefore analysed our tumor panel by 2-color interfase FISH hybridization with a chromosome 17 centromere probe and a nm23-H1 and H2 containing BAC clone. All N-myc ampli®ed tumors clearly showed gain of 17q, as we always found one or two additional nm23 copies compared to the centromere. In the N-myc single copy tumors the 17q status showed major heterogeneity within individual tumors. The two tumors (N86, N179) showed only numerical abnormalities of the entire chromosome 17. Flow cytometry showed both tumors to be triploid. Tumor N52 showed in 82% of the nuclei 2 centromeres and 2 telomeres, indicating an absence of gain. Three N-myc single copy tumors showed a clear 17q gain in the majority of the nuclei. These three tumors (N68, N98, N160) showed a high nm23-H1 and H2 expression (Figure 3 ). In the remaining ®ve N-myc single copy tumors we found a range of dierent interfase patterns within each sample. These tumors showed in 20 ± 40% of the nuclei extra copies of nm23, relative to the number of centromere spots. The tumors showing this surprising heterogeneity have in general a lower nm23-H1 and H2 expression than the tumors with a homogeneous gain of 17q. These data suggest that nm23-H1 and H2 can be up-regulated in neuroblastoma both by gene dosage (17q gain) and transcriptional activation (N-myc overexpression).
The common region of 17q gain harbors many candidate genes for a role in tumorigenesis. Cytogenetic mapping studies identi®ed SMS-KCNR as the cell line with the smallest 17q amplicon, starting distal of D17S791 (361 cR) and extending to the telomere (Lastowska et al., 1998) . Nm23-H1 and H2 have been mapped at 398 cR (www.genome.wi.mit.edu). To check whether both genes indeed map within the SMS-KCNR amplicon, we performed 2-color FISH. Metafase FISH with a chromosome 17 centromere probe and a BAC of D17S791 showed no evidence of gain (centromere to D17S791 ratio 2 : 2, Figure 4a) . A nm23-H1 and H2 containing BAC clone showed a clear increase in copy number (centromere:nm23 ratio of 2 : 3, Figure 4b ). Nm23-H1 and nm23-H2 therefore map in the minimal region of 17q gain in neuroblastoma cell lines, close to the proximal border of this region.
To screen for activating mutations we sequenced the entire coding regions of both nm23-H1 and nm23-H2 in 25 neuroblastomas. cDNA from 21 neuroblastomas used for the expression analysis and four additional tumor samples were sequenced but no mutations were found. This suggests that activation of nm23 by point mutations does not play a substantial role in neuroblastoma.
N-myc can functionally replace c-myc in transgenic mice (Malynn et al., 2000) , suggesting that at least part of their targets are shared. Therefore, we studied the expression of nm23-H1 and H2 in a c-myc transfected melanoma cell line E10 and its mock transfected control MD3A (Versteeg et al., 1988) . The up-regulation of c-myc results in a clear increase of nm23-H1 and nm23-H2 mRNA levels ( Figure 1a) . Recently, Schuhmacher et al. (2001) demonstrated that c-myc can induce nm23-H1 in human B cells. Together with our data of the swift up-regulation of nm23-H1 and nm23-H2 by N-myc and the induction by c-myc in melanoma cell lines, this suggests that nm23-H1 and H2 are major targets of the myc family of oncogenes.
Gain of the short arm of chromosome 17 has been one of the most enigmatic aberrations observed in neuroblastoma. The extra 17q copies often result from chromosomal translocations, but the breakpoints are scattered over a large area of the 17q arm. Therefore, a gene dosage eect of one or more genes on the extra copy of the 17q arm has been postulated. The minimal region of gain includes 17q21.3 to 17qter a region of several hundred cR, which makes identi®cation of such postulated genes dicult.
This study shows that the 17q genes nm23-H1 and nm23-H2 are early downstream targets of N-myc. Although this study does not address the question whether the nm23 genes are direct targets of the N-myc transcription factor, our analysis showed that they are activated relatively early in the N-myc downstream pathway. Moreover, our analysis suggests that nm23-H1 and H2 can be up-regulated in neuroblastoma both by gene dosage (17q gain) and transcriptional activation (N-myc overexpression). In tumors with both 17q gain and N-myc ampli®cation, these mechanisms work synergistically. A 10-fold transcriptional induction in N-myc ampli®ed cells will lead to a 20-fold induction when the nm23-H1 and H2 copy numbers are doubled. The up-regulation of nm23-H1 and H2 provides a ®rst evidence for a functional relation between 17q gain and N-myc ampli®cation in human neuroblastoma and provides new clues to understanding neuroblastoma tumorigenesis.
